Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Nick Leschly
Pharma
2022 forecast: Cell, gene therapy makers have high hopes
Novartis, BMS and Gilead are among the companies expected to bring in high revenues from their cell and gene therapies in 2022.
Arlene Weintraub
Dec 22, 2021 3:00am
New-look bluebird moves HQ from Cambridge to nearby Somerville
Nov 5, 2021 2:30pm
Bluebird’s Zynteglo snag could spell trouble for gene therapies
Feb 18, 2021 11:51am
Bluebird tanks with FDA delay of LentiGlobin in sickle cell
Nov 5, 2020 10:58am
BMS, bluebird bio scramble after FDA rebuffs CAR-T submission
May 13, 2020 10:35am
JPM sound bites: The jokes you missed at this year's meeting
Jan 16, 2020 2:37pm
